Dynavision D2 for Stroke

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Providence Care Hospital, Kingston, Canada
Stroke+3 More
Dynavision D2 - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this research is to determine the effectiveness of using the Dynavision D2 to improve left neglect in adults with brain injury, and improve performance of ADLs/IADLs. This study will use a randomized control trial at Providence Care Hospital in Kingston Ontario, with clients admitted to the Stroke and ABI services who have been identified through the Catherine Bergego Scale (CBS) as having moderate to severe left neglect. Individuals will be randomly assigned to the control arm, where they will get the usual 60 minutes of OT treatment daily or the intervention arm, which is 30 minutes of their usual OT treatment and a 30 minute session of the Dynavision for 10 sessions for short stay inpatients (~ 3 weeks) and 20 sessions for clients with longer 5-6 week stay. The CBS will be used to measure change in neglect severity at three time points: baseline, following 10 sessions and following 20 sessions, for those that stay for longer.

Eligible Conditions

  • Stroke
  • Injuries, Acute Brain

Treatment Effectiveness

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: ~5-6 weeks from baseline

~3 weeks from baseline
Mean change from baseline score on Catherine Bergego Scale after 10 therapy sessions
Mean change from baseline score on Letter Cancellation Test after 10 therapy sessions
Mean change from baseline score on Star Cancellation Test after 10 therapy sessions
~5-6 weeks from baseline
Mean change from baseline score on Catherine Bergego Scale after 20 therapy sessions
Mean change from baseline score on Letter Cancellation Test after 20 therapy sessions
Mean change from baseline score on Star Cancellation Test after 20 therapy sessions

Trial Safety

Trial Design

2 Treatment Groups

Usual Treatment
1 of 2
Repetitive Visual Scanning Training
1 of 2
Active Control
Experimental Treatment

40 Total Participants · 2 Treatment Groups

Primary Treatment: Dynavision D2 · No Placebo Group · N/A

Repetitive Visual Scanning Training
Device
Experimental Group · 1 Intervention: Dynavision D2 · Intervention Types: Device
Usual TreatmentNoIntervention Group · 1 Intervention: Usual Treatment · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: ~5-6 weeks from baseline
Closest Location: Providence Care Hospital · Kingston, Canada
Photo of ontario 1Photo of ontario 2Photo of ontario 3
2020First Recorded Clinical Trial
1 TrialsResearching Stroke
5 CompletedClinical Trials

Who is running the clinical trial?

Ontario Society of Occupational TherapistsUNKNOWN
1 Previous Clinical Trials
3 Total Patients Enrolled
Queen's UniversityLead Sponsor
299 Previous Clinical Trials
76,038 Total Patients Enrolled
4 Trials studying Stroke
1,114 Patients Enrolled for Stroke

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have been neglected by your caregiver for at least 6 months.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.